GlassScriptPhysician profile
Catherine Chan
NPI 1821697525
$6,763.89
in general payments reported to CMS, 2019-2025
35 companies · $405 in 2025
The $405 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,966 · 2022: $1,354 · 2023: $611 · 2024: $429 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,277.67 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $755.35 | 2022-2025 | |
| Incyte Corporation | $708.58 | 2021-2023 | Pemazyre, Monjuvi |
| Lilly USA, LLC | $485.01 | 2021-2022 | |
| Glaxosmithkline, LLC. | $482.07 | 2021-2025 | Blenrep, Ojjaara |
| Merck Sharp & Dohme LLC | $475.00 | 2021-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $449.48 | 2021-2025 | Enhertu, Imfinzi |
| Janssen Biotech, INC. | $317.51 | 2021-2024 | Rybrevant |
| Jazz Pharmaceuticals INC. | $301.14 | 2021-2024 | |
| Amgen INC. | $286.97 | 2021-2023 | Lumakras |
| Bayer Healthcare Pharmaceuticals INC. | $279.03 | 2021-2023 | |
| Astellas Pharma US INC | $250.06 | 2021-2023 | Padcev |
| Pharmacyclics LLC, An Abbvie Company | $186.84 | 2021 | |
| Deciphera Pharmaceuticals INC. | $184.08 | 2023-2024 | Qinlock |
| Karyopharm Therapeutics INC. | $183.33 | 2021-2022 | |
| Pfizer INC. | $182.65 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $128.84 | 2021-2022 | |
| Eisai INC. | $125.24 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $110.56 | 2021-2023 | Opdivo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.14 | 2021 | |
| Beigene USA, INC. | $104.24 | 2021 | |
| Stemline Therapeutics INC. | $80.76 | 2025 | Orserdu |
| Genzyme Corporation | $78.44 | 2021 | |
| Seagen INC. | $66.58 | 2021-2023 | Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $57.24 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $46.74 | 2021-2022 | |
| Emd Serono, INC. | $46.34 | 2021 | |
| Celgene Corporation | $45.28 | 2021 | |
| Alexion Pharmaceuticals, INC. | $43.38 | 2021 | |
| Abbvie INC. | $41.76 | 2024-2025 | |
| Daiichi Sankyo INC. | $38.74 | 2024-2025 | Enhertu, Vanflyta |
| Kite Pharma, INC. | $28.14 | 2021 | |
| Acrotech Biopharma INC. | $24.77 | 2021 | |
| Sobi, INC | $24.65 | 2021 | |
| Morphosys, US INC. | $21.00 | 2021 | |
| Puma Biotechnology, INC. | $17.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.